Daniel Brewer is Senior Lecturer in Cancer Bioinformatics in the Norwich Medical School at UEA. He leads the bioinformatics team within the Cancer Genetics Group. His research is exploring how to draw on methods such as data science and machine learning for detecting cancer and improve the lives of those suffering with cancer. This includes detecting the biomarkers that can signal the state of progression in prostate cancer, identifying bacteria present in prostate cancer and what this means, and exploring different sub-types of prostate cancer.
His work his designed to address the presence and levels of aggression of prostate cancer, to understand the disease in more detail and to contribute to faster and more effective cancer management and treatments.
Areas of Expertise (5)
University College London: Ph.D., Computational Biology 2005
University College London: M.Res., Biological Complexity 2002
Imperial College, London: M.Sci., Physics 2000
Media Appearances (5)
Cancer vaccines could save thousands after experts find viruses that may trigger the disease
The Sun online
University of East Anglia expert Dr Daniel Brewer said: “There is strong evidence that viruses play a role in the development of cancer. “If there is a virus, then you can develop a vaccine to prevent it or slow it down.”
New vaccine hope as viruses are discovered in one in eight tumours, fuelling prospect of scientists developing preventative jabs
Daily Mail online
Study co-author Dr Daniel Brewer, of the University of East Anglia, said: 'We found viruses in 23 different types of cancer, including those where no previous link has been established. These include prostate, breast, lung, kidney, bladder, colon and skin cancer. 'This is important because finding new links between infection and cancer types has the potential to provide vaccines, such as the HPV vaccine, which could reduce the global impact of cancer.'
Prostate cancer URINE test could diagnose disease 5 years earlier than current methods
The experimental new test called ‘PUR’ (Prostate Urine Risk) also identifies men who are up to eight times less likely to need treatment within five years of diagnosis. The breakthrough by British scientists could help thousands of men avoid an unnecessary biopsy. It may also dramatically reduce the number of repeat follow-up operations for 'low risk' patients on active surveillance.
Prostate cancer: New urine test hope
BBC News online
Current PSA blood tests cannot do this, meaning many men experience unnecessary worry, investigations and treatment. The prostate urine risk (PUR) test looks for genetic markers to give a more accurate assessment. Trials in 537 patients suggest it can reliably sort men by risk.
Urine tests could reveal whether men have prostate cancer five years early
The Sun online
A simple urine test can reveal whether men have aggressive prostate cancer five years earlier than currently, researchers claim. It could help thousands get life- saving treatment earlier and spare many more from needless painful biopsies.
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targetsNature Genetics
2018 Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples.
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence dataPLoS One
2017 A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer.
DESNT: a poor prognosis category of human prostate cancerEuropean Urology Focus
2017 A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading to substantial overtreatment. It remains an enigma that, in contrast to breast cancer, unsupervised analyses of global expression profiles have not currently defined robust categories of prostate cancer with distinct clinical outcomes.
The evolutionary history of lethal metastatic prostate cancerNature
2015 Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths.
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissueNature
2015 Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer.